Redbiotec was founded in 2006 as an ETH spin-off.  Having sold its CMV vaccine business to Pfizer in 2015, Redbiotec has since developed potent HSV-2 immunotherapies, and a platform technology of engineered bacteria - BRISPR® - to deliver therapeutic cargos of various nature for the treatment of cancer and genetic disorders.

Location

Wagistrasse 23, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2006

  • Number of employees in Switzerland

    10-19

Key business